ES2060045T3 - Procedimiento para reducir el tamaño del cristal del dihidrato de hidrocloruro de ondansetron. - Google Patents

Procedimiento para reducir el tamaño del cristal del dihidrato de hidrocloruro de ondansetron.

Info

Publication number
ES2060045T3
ES2060045T3 ES90307044T ES90307044T ES2060045T3 ES 2060045 T3 ES2060045 T3 ES 2060045T3 ES 90307044 T ES90307044 T ES 90307044T ES 90307044 T ES90307044 T ES 90307044T ES 2060045 T3 ES2060045 T3 ES 2060045T3
Authority
ES
Spain
Prior art keywords
reduce
hydrochloride dihydrate
crystal size
procedure
ondansetron hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90307044T
Other languages
English (en)
Inventor
David Trevor Collin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10659180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2060045(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2060045T3 publication Critical patent/ES2060045T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Otolaryngology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)

Abstract

LA INVENCION ES RELATIVA A UN PROCESO PARA REDUCIR EL TAMAÑO DE CRISTAL DE CIERTO HIDROCLORURO DIHIDRATO PRODUCIDO POR CRISTALIZACION DE UN DISOLVENTE A UN TAMAÑO EL CUAL ES ADECUADO PARA DISTRIBUCION EFECTIVA EN UNA TABLETA DE MEZCLA, EN PARTICULAR MENOR DE 250(MU)M EN UN 100%. EL HIDROCLORURO DIHIDRATO SE DISUELVE PARA SECARLO A ELEVADA TEMPERATURA Y REDUCIDA PRESION ATMOSFERICA Y ENTONCES SE REHIDRATA
ES90307044T 1989-06-28 1990-06-27 Procedimiento para reducir el tamaño del cristal del dihidrato de hidrocloruro de ondansetron. Expired - Lifetime ES2060045T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898914804A GB8914804D0 (en) 1989-06-28 1989-06-28 Process

Publications (1)

Publication Number Publication Date
ES2060045T3 true ES2060045T3 (es) 1994-11-16

Family

ID=10659180

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90307044T Expired - Lifetime ES2060045T3 (es) 1989-06-28 1990-06-27 Procedimiento para reducir el tamaño del cristal del dihidrato de hidrocloruro de ondansetron.

Country Status (20)

Country Link
US (1) US5622720A (es)
EP (1) EP0415522B1 (es)
JP (1) JP3093242B2 (es)
KR (1) KR0182789B1 (es)
AT (1) ATE110380T1 (es)
AU (1) AU637110B2 (es)
CA (1) CA2019944C (es)
DE (1) DE69011786T2 (es)
DK (1) DK0415522T3 (es)
ES (1) ES2060045T3 (es)
GB (1) GB8914804D0 (es)
HK (1) HK44495A (es)
HU (1) HU208009B (es)
IE (1) IE64715B1 (es)
IL (1) IL94888A (es)
NZ (1) NZ234267A (es)
RU (1) RU2002745C1 (es)
SA (1) SA90110025B1 (es)
UA (1) UA18249A (es)
ZA (1) ZA905002B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
RU2162695C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона гидрохлорида дигидрата, субстанция и фармацевтический препарат
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
RU2185825C1 (ru) * 2001-03-12 2002-07-27 Государственный научный центр - Институт биофизики Фармацевтическая композиция, содержащая ондансетрон и метацин
CN100379723C (zh) * 2002-02-19 2008-04-09 特瓦制药工业有限公司 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙
EP1485344A1 (en) 2002-03-28 2004-12-15 Synthon B.V. Venlafaxine besylate
PT1499623E (pt) * 2002-04-29 2007-08-10 Teva Gyogyszergyar Zartkoeruee ''processo papa a preparação de 1, 2, 3, 9-tetra-hidro-9-metil-3- [(2-metil-1h-imidazol-1-il) metil] -4h-carbazol-4-ona''
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
WO2005108392A2 (en) 2004-05-07 2005-11-17 Taro Pharmaceutical Industries Ltd. Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
WO2006091657A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
ZA200707469B (en) * 2005-02-23 2008-11-26 Teva Pharma Rasagiline formulations of improved content uniformity
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
CN101573106B (zh) * 2006-10-24 2013-07-24 赫尔辛医疗股份公司 具有改进的稳定性和生物利用度的含帕洛司琼盐酸盐的软胶囊剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88268I2 (es) * 1984-01-25 1994-02-03
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
EP0275668B1 (en) * 1986-12-17 1992-09-30 Glaxo Group Limited Use of ketone derivatives in the treatment of cognitive disorders
DK185489A (da) * 1988-04-22 1989-10-23 Duphar Int Res Imidazolylmethyl-cycloalkanoebaaindoloner, deres fremstilling og anvendelse
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron

Also Published As

Publication number Publication date
UA18249A (uk) 1997-12-25
JP3093242B2 (ja) 2000-10-03
SA90110025B1 (ar) 2001-03-24
HK44495A (en) 1995-03-31
AU5787490A (en) 1991-01-03
IL94888A0 (en) 1991-04-15
EP0415522A1 (en) 1991-03-06
IL94888A (en) 1995-03-15
JPH0395178A (ja) 1991-04-19
HU904015D0 (en) 1990-12-28
CA2019944A1 (en) 1990-12-28
ATE110380T1 (de) 1994-09-15
NZ234267A (en) 1992-11-25
IE64715B1 (en) 1995-08-23
AU637110B2 (en) 1993-05-20
KR0182789B1 (ko) 1999-10-15
DE69011786T2 (de) 1994-12-15
KR910000709A (ko) 1991-01-30
RU2002745C1 (ru) 1993-11-15
DK0415522T3 (da) 1994-09-19
IE902333L (en) 1990-12-28
HUT54140A (en) 1991-01-28
CA2019944C (en) 2000-05-09
DE69011786D1 (de) 1994-09-29
US5622720A (en) 1997-04-22
GB8914804D0 (en) 1989-08-16
IE902333A1 (en) 1991-01-16
HU208009B (en) 1993-07-28
EP0415522B1 (en) 1994-08-24
ZA905002B (en) 1991-12-24

Similar Documents

Publication Publication Date Title
ES2060045T3 (es) Procedimiento para reducir el tamaño del cristal del dihidrato de hidrocloruro de ondansetron.
ES2113881T3 (es) Derivados y analogos de acido 2-desoxi-2,3-didehidro-n-acetil neuraminico y su utilizacion como agentes antivirales.
ES2047342T3 (es) Productos autoestables de arroz y procedimientos para su produccion.
ES2174992T3 (es) Productos intermediarios para la obtencion de compuestos inhibidores de proteasas retrovirales.
MX9401388A (es) Compuestos que inhiben la proteasa retroviral y composiciones farmaceuticas que los incluyen.
ES2174921T3 (es) Inhibidores de la proteasa del vih.
ES2113682T3 (es) Procedimiento y dispositivo para la limpieza de elementos solidos.
ES461415A2 (es) Procedimiento para la preparacion de vacunas acelulares.
AR010938A1 (es) Procedimiento para preparar acido l-ascorbico.
NO872671L (no) 4-benzyloksy-3-pyrrolin-2-on-1-yl-acetamid, fremstilling og anvendelse derav.
ES8403912A1 (es) Procedimiento de preparacion de un nuevo derivados de la tioformamida.
ES8404373A1 (es) Un procedimiento para obtener compuestos de ribofuranosilselenazol-4-carboxamida.
SE7610217L (sv) Kristallint dipilokarpiniumpamoat
ES2151891T3 (es) Derivados de ciclohexano sustituidos con imidazolilo.
ES2191035T3 (es) Derivados de la pirona como inhibidores de la proteasa y agentes antiviricos.
CH418527A (fr) Procédé de préparation de la vitamine B12
ES2097002T3 (es) Procedimiento para convertir loracarbef dihidrato en loracarbef monohidrato.
ES2042571T3 (es) N-(s-3-metilftanoil)-d-gamma-glutamil-glicil-d-alanina cristalina, y procedimientos y productos intermedios de la misma.
MX9401456A (es) Derivados novedosos del acido 3-hidroxiantranilico, proceso para su preparcion y formulaciones farmaceuticas que los incluyen.
IT1064766B (it) Processo per la preparazione di aih3(po4)2,3h2o
JPS5253878A (en) Process for preparing 2-alkoxy-3h-azepines
IT7920146A0 (it) Procedimento per la preparazione di derivati del tiazolo, particolarmente utili come medicamenti.
ES471088A1 (es) Un procedimiento para la preparacion de derivados de 2-oxa- zolidinona
ES472270A1 (es) Un procedimiento para la produccion de derivados 4-n-susti- tuidos de fortimicina b
ES178468A2 (es) Mejoras en la principal

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 415522

Country of ref document: ES